In this issue:
Serious infection risk with adalimumab for hidradenitis suppurativa
IL-17 inhibitors not associated with increased risk of early MACE
Infection risk with JAK inhibitors vs biologics for atopic dermatitis
Amlitelimab for atopic dermatitis
Biologics for paediatric plaque psoriasis
Ustekinumab biosimilar, BAT2206, for moderate-to-severe psoriasis
Biologic therapy and malignancy risk in psoriasis
Real-world outcomes of bimekizumab for psoriasis
Optimal sequential therapy after secondary IL-17A inhibitor failure
Kuwait consensus statements on biologics for chronic plaque psoriasis
Please login below to download this issue (PDF)